经导管主动脉瓣植入术并发感染性心内膜炎
本文综述了经导管主动脉瓣植入术后感染性心内膜炎(TAVI-IE)的流行病学、病原学、危险因素、诊断与治疗。TAVI-IE 1年发生率0.2%-3.1%,常见病原体为肠球菌、金黄色葡萄球菌和凝固酶阴性葡萄球菌;随着TAVI向低危人群扩展,绝对病例数可能上升。超声诊断困难,辅助影像作用尚在探索;治疗类似传统人工瓣膜心内膜炎,手术时机与获益人群缺乏明确证据。
要点
- TAVI-IE 1年发生率0.2%-3.1%,常见病原体为肠球菌、金黄色葡萄球菌和凝固酶阴性葡萄球菌。
- younger age at implant 和显著残余主动脉瓣反流是重要危险因素。
- 治疗以长期静脉抗生素为基础,手术干预的作用与时机尚不明确。
核心结论
- TAVI-IE相对罕见但随TAVI向低危人群扩展绝对病例数可能上升,诊断和治疗仍具挑战。
研究设计与样本
- 综述,总结TAVI-IE的文献证据。
主要发现
- TAVI-IE 1年发生率为0.2%-3.1%。
- 常见病原体为肠球菌、金黄色葡萄球菌和凝固酶阴性葡萄球菌。
- 重要危险因素包括植入时较年轻和显著残余主动脉瓣反流。
- 超声心动图诊断TAVI-IE可能具有挑战性,MSCT和18FDG PET等辅助影像作用仍在显现。
关键数值与推荐
- TAVI-IE治疗与常规人工瓣膜心内膜炎(PVE)大致平行,以长期静脉抗生素治疗和考虑手术干预为基石。
- 心脏手术在TAVI-IE中的确切作用和时机尚未定义,缺乏明确证据帮助识别应接受手术的患者。
- 减少不必要的医疗干预(TAVI期间和之后)及使用适当的抗生素预防可能有助于预防TAVI-IE,但缺乏稳健证据支持特定预防策略。
临床怎么用
- 对TAVI术后患者应警惕感染性心内膜炎,关注年轻植入者和显著残余主动脉瓣反流者。
- 诊断困难时可考虑MSCT和18FDG PET等辅助影像,但需进一步研究选择患者。
- 治疗参照PVE,长期静脉抗生素,手术干预需个体化评估。
局限性
- 特定预防策略缺乏稳健证据。
- 高级混合影像的患者选择需进一步研究。
- 手术管理和预防策略的证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infective endocarditis complicating transcatheter aortic valve implantation (TAVI-IE) is a relatively rare condition with an incidence of 0.2%-3.1% at 1 year post implant. It is frequently caused by Enterococci, Staphylococcus aureus and coagulase negative staphylococci While the incidence currently appears to be falling, the absolute number of cases is likely to rise substantially as TAVI expands into low risk populations following the publication of the PARTNER 3 and Evolut Low Risk trials. Important risk factors for the development of TAVI-IE include a younger age at implant and significant residual aortic regurgitation. The echocardiographic diagnosis of TAVI-IE can be challenging, and the role of supplementary imaging techniques including multislice computed tomography (MSCT) and positron emission tomography (18FDG PET) is still emerging. Treatment largely parallels that of conventional prosthetic valve endocarditis (PVE), with prolonged intravenous antibiotic therapy and consideration of surgical intervention forming the cornerstones of management. The precise role and timing of cardiac surgery in TAVI-IE is yet to be defined, with a lack of clear evidence to help identify which patients should be offered surgical intervention. Minimising unnecessary healthcare interventions (both during and after TAVI) and utilising appropriate antibiotic prophylaxis may have a role in preventing TAVI-IE, but robust evidence for specific preventative strategies is lacking. Further research is required to better select patients for advanced hybrid imaging, to guide surgical management and to inform prevention in this challenging patient cohort.
引用
- Harding D, Cahill TJ, Redwood SR, et al. Infective endocarditis complicating transcatheter aortic valve implantation. Heart. 2020. PMID: 31932285. doi:10.1136/heartjnl-2019-315338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。